Wise Ally International Holdings Limited Overview
Wise Ally is a small-cap, founder-controlled, Hong Kong-headquartered electronics manufacturing services (EMS) provider. It sells full turnkey solutions: design development and enhancement, engineering, procurement, production, quality control and logistics. Its outputs are printed circuit board assemblies (PCBAs), multifunctional modules and finished electronic products for consumer, appliance, commercial and industrial control, HVAC, IoT and medical/healthcare customers.
The business is rooted in the Defond Group's 45-plus-year electro-mechanical heritage. It produces mainly from a leased facility in Chang'an Town, Dongguan. Since 2024 it has added a "China Plus One" production arrangement in Batam, Indonesia, through partner Giken Sakata.
Revenue of HK$855 M (FY2025) is concentrated: the top five customers took 51.3% of sales, and the US alone took 45.8%. After a record FY2024, the company has swung to losses. US tariff escalation, order deferrals and component inflation drove a FY2025 net loss of HK$31.2 M and a 1H2026 loss of HK$54.6 M. A net-cash balance sheet (HK$133.9 M at 30 June 2026) is its principal buffer.
What the company does
Wise Ally's filings describe the Company as an investment holding company. Its subsidiaries are principally engaged in the manufacturing and sale of electronic products (FY2025 annual results, Note 1). In fuller descriptions the company presents itself as an established EMS provider offering full turnkey solutions, with particular focus on consumer electronic products. It also offers a wide range of EMS services to customers in the medical, healthcare, HVAC, industrial and appliance segments, and IoT end-device solutions (voluntary JV announcement, 20 March 2024).
The February 2023 tenancy announcement lists the product applications served as appliances, commercial control, vapour products and HVAC. Aggregator profiles (Yahoo Finance, Morningstar) add medical and healthcare product work. These profiles cite wearable bio-sensors, oximeters, heart-rate sensors and fertility-hormone testers. They also cite validation services: design, clean room, assembly process, part moulding, packaging and sterilisation validation.
The company website organises the offering into five industries and six service lines:
Industries: Consumer Electronics; HVAC; Commercial and Industrial Appliances; Internet of Things (IoT); Medical and Healthcare.
Services: Design and Engineering; Supply Chain Management; Contract Manufacturing and Lean Production Management; Clean Room Facility; Total Quality Management; Connected Solutions.
Business model and revenue model
Revenue model. Product sales account for essentially 100% of revenue. All revenue is from contracts with customers and is recognised at a point in time (FY2025 annual results, Note 3). There is no reported service, subscription or licensing revenue line.
Engineering and design work is monetised inside the unit price of manufactured product. In some ODM/JDM arrangements it may be monetised through NRE (non-recurring engineering) charges, but no breakdown is disclosed.
Customer engagement model. The business is build-to-order against customer purchase orders. Contract liabilities (customer advances) stood at HK$26.6 M at end-FY2025 and HK$21.0 M at 30 June 2026. All unsatisfied performance obligations have an expected duration of under one year. This confirms limited multi-year contracted backlog visibility.
Credit terms. Customers receive credit terms of 15–120 days. Sales proceeds are predominantly in USD. Part of the cost base (labour, rent, some materials) is in RMB, which creates a structural USD/RMB exposure.
Model evolution:
2021–2023: Management pursued "own brand" products. Arthur Chu was hired in January 2021 as Managing Director of a New Branded Division. In the floor-care category, the group also made a HK$46 M investment in Talentone Technology Limited (TTL), a licensed-trademark vacuum cleaner distributor. TTL produced fair-value losses and was exited in February 2025.
2024: Management highlighted successful ODM (Original Design Manufacturer) and JDM (Joint Development Manufacturing) projects in consumer electronics. It said it would widen turnkey capability to include software, firmware and electro-mechanical design optimisation (FY2024 annual results, Prospects).
Value chain position
Wise Ally sits in the mid-tier, high-mix/mid-volume segment of the EMS value chain. Relative to Tier-1 EMS players (Foxconn, Jabil, Flex), it is a niche, engineering-led contract manufacturer. Upstream it buys semiconductors, passive components, PCBs, plastics and metal parts. Purchasing is relatively fragmented: the largest supplier was 5.2% and the top five 22.8% of FY2025 purchases (AR2025). Downstream it ships to brand-owner customers' factories and distribution hubs. That explains the prominence of the Philippines, Chinese Mainland, Malaysia, Ireland and Mexico as "delivery location" countries, alongside end-markets such as the US.
Customer types and end-markets
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Largest 10%+ customer revenue (HK$ M) | 132.4 | 158.8 | 191.1 | 254.0 | 143.6 |
| Number of customers above 10% of revenue | 3 | 3 | 2 | 3 | 2 |
| Largest customer share of revenue (%) (derived) | 12.6 | 11.9 | 15.6 | 20.1 | 16.8 |
Customers are overseas brand owners and OEMs. Customer names are not disclosed; filings identify them only as Customer A/B/C. Concentration is high and rising:
Sources: annual results Note 3(a) for each year. The FY2025 largest-customer share of 16.8% and the top-five share of 51.3% are from AR2025, Major Customers and Suppliers. In 1H2026 two customers exceeded 10%: HK$52.5 M (16.8% derived) and HK$37.6 M (12.1% derived).
The end-markets served are household appliances; commercial controls (e.g., commercial catering and appliance controllers); vapour products; HVAC controls; IoT end devices; medical and healthcare devices; and consumer electronics. No revenue split by application has been disclosed since listing.
Independent characterisation
Wise Ally is effectively a single-plant-centric, customer-concentrated EMS house. Its earnings are highly operationally geared to a handful of programmes. The FY2024 record profit of HK$72.2 M was built on new-product ramps at a few key customers, a favourable product mix and lower material costs. It also included a HK$19.2 M non-cash fair-value write-back on the TTL convertible bond. FY2025–1H2026 shows the reverse operating leverage: revenue down 32–34% wiped out gross profit.
The structural question is whether the Batam "China Plus One" arrangement can win enough US-bound programmes, and whether facility consolidation in Dongguan can re-base fixed costs, to restore a profitable scale. In 1H2026 the US reached 64.2% of sales.
Strategy
Stated strategic themes (latest annual report and interim)
Management's recurring strategic themes in AR2025 (Chairman's Statement) and the 1H2026 announcement are:
-
"China Plus One" manufacturing diversification. China operations remain the cornerstone, providing scale and efficiency. Batam, Indonesia is described as offering competitive labour costs, proximity to key markets and a stable operating environment. It is pivotal to winning new US customers amid tariffs.
-
Financial discipline and deleveraging.
-
Bank borrowings were cut 47.6% in FY2025 and a further 38.0% in 1H2026.
-
Net finance costs fell 80.1% in FY2025.
-
In 1H2026 interest income on deposits fully covered bank interest expense, giving net interest income of about HK$67,000.
-
-
Prudent procurement, inventory and receivables management. This includes moderating procurement in response to raw-material inflation and stricter receivables enforcement.
-
Customer-base and footprint diversification.
-
Structural cost optimisation (new in 1H2026). This means consolidating manufacturing facilities to improve footprint efficiency, reduce fixed overheads and optimise structural operating costs.
Strategic initiatives — last 24 months
| Initiative | Date | Description | Status / targets |
|---|---|---|---|
| Batam production via Giken Sakata / WiseGiken Elite JV | JV signed 20 Mar 2024; full-scale production early 2024; ramp accelerated through FY2025 | Partner manufacturing for US-bound programmes; Wise Ally on-site team supported from China | Ongoing. FY2024 MD&A stated plans to expand Batam capacity further. No capacity or revenue targets disclosed. |
| ODM/JDM and turnkey expansion | Stated in FY2024 results (Mar 2025) | Expand in-house software, firmware, electronics and electro-mechanical design capabilities | No quantified target |
| University / industry collaboration on AI- and 5G-enabled products, including application-specific robotics | Stated Mar 2025 | Collaborations in the HKSAR and China | No partners named; status not updated in FY2025 or 1H2026 filings |
| Electric vehicle (EV) sector entry | Stated Mar 2025 | Identify EV component and technology opportunities leveraging electro-mechanical expertise | No contracts disclosed |
| Trade-show participation | Stated Mar 2025 | Increase presence at international trade shows | — |
| Deleveraging programme | 2024–2026 | Cut bank borrowings | Achieved: HK$292.6 M (end-2023) to HK$61.2 M (June 2026) |
| Exit of TTL / floor-care investment | Feb 2025 | Portfolio streamlining | Completed |
| Facility consolidation | Announced 26 Aug 2026 | Consolidate manufacturing facilities and reduce fixed overheads | No cost-savings target or timeline disclosed |
| ESG | Ongoing | ISO 14001 system; CSR (Caring Company scheme); charitable donations of HK$555,000 in FY2025 | No emissions targets identified in reviewed documents |
Medium-term financial targets / guidance
None disclosed. Wise Ally provides no quantitative revenue, margin or profit guidance. Its outlook statements are qualitative. The 1H2026 statement says the remainder of 2026 will remain challenging. The group will focus on expanding its client portfolio, diversifying production and protecting core profitability.
Products & Services
Wise Ally does not publish a product-level revenue breakdown, product launch dates or pricing. The catalogue below is compiled from the company website, filings and data-vendor profiles. Pricing is contract-specific and not publicly disclosed for every line.
Manufacturing outputs (by build level)
| Offering | Description / capabilities | Target customer | Pricing model |
|---|---|---|---|
| Printed circuit board assemblies (PCBAs) | SMT and through-hole assembly of control boards for appliances, HVAC controllers, commercial controls and medical devices | OEMs and brand owners needing board-level supply | Unit price per board under PO; not publicly disclosed |
| Multifunctional modules | Sub-assemblies integrating PCBA with displays, sensors, enclosures and electro-mechanical parts | Appliance and industrial OEMs | Unit price; not publicly disclosed |
| Finished electronic products (box build) | Complete devices including enclosure, packaging and test | Consumer, IoT and medical brand owners | Unit price; not publicly disclosed |
Application / industry portfolio (website taxonomy plus filings)
| Industry vertical | Representative products (as disclosed) | Notes | Source |
|---|---|---|---|
| Consumer Electronics | Consumer devices built under ODM/JDM and EMS models | The FY2024 annual results cite successful ODM/JDM projects that entered mass production in early 2024 | Website; FY2024 annual results |
| HVAC | Heating, ventilation and air-conditioning controls | Named application since IPO era | Tenancy announcement 2023; website |
| Commercial and Industrial Appliances | Commercial controls and appliance electronics | "Appliances" and "commercial control" are named applications | Tenancy announcement 2023; website |
| Vapour products | Electronic vapour devices / electronics | Named product application in 2023 group description and data-vendor profiles. Current share not disclosed. | Tenancy announcement 2023; dividend.watch / Yahoo profile |
| Internet of Things (IoT) | Connected end-device solutions, tailored to client applications | Proceeds earmarked at IPO for IoT R&D (HK$4.0 M) | Website; FY2021 Use of Proceeds |
| Medical and Healthcare | Wearable bio-sensor, oximeter, heart-rate sensors, fertility-hormone tester. Services include design validation, clean room validation, assembly process validation, part moulding validation, packaging validation, sterilisation validation, and risk management (planning, assessment, mitigation, control). | Clean room facility listed as a service line | Morningstar and Yahoo profiles; website |
Service lines (website)
| Service | Scope |
|---|---|
| Design and Engineering | Product design development and enhancement, technical advice, engineering solutions. Turnkey software/firmware and electro-mechanical design optimisation is targeted for expansion (FY2024 Prospects). |
| Supply Chain Management | Material selection and procurement through a global vendor network. The supply base is managed by a VP of Supply Base Management (Ms. Choi Yuet Mei). |
| Contract Manufacturing and Lean Production Management | High-mix production in Dongguan, plus partner production in Batam |
| Clean Room Facility | Clean-room assembly for medical/healthcare products |
| Total Quality Management | ISO 9001 quality management at the Chang'an factory; ISO 14001 environmental management |
| Connected Solutions | IoT connectivity and end-device solutions |
Discontinued / exited initiatives
| Initiative | Status |
|---|---|
| New Branded Division (own-brand products, from Jan 2021) | No revenue disclosed. Its head, Arthur Chu, remains an Executive Director. Not separately reported. |
| Floor-care products via Talentone Technology Ltd (licensed trademark of a "Fortune 100" licensor; vacuum cleaners for the US market) | Exited February 2025 (stake sold for HK$0.73 M; CB principal repaid via chairman's undertaking) |
Financial Narrative
All figures are HK$ M and fiscal years end 31 December. Sources are the FY2021, FY2023, FY2024 and FY2025 annual results announcements and AR2025. Each announcement contains two years of comparatives; the five-year summary is in AR2025.
Income statement
Notes:
EBITDA: FY2023 EBITDA (HK$62.9 M) is from the FY2024 announcement comparatives. FY2021–FY2022 full-year EBITDA was not presented in the documents reviewed.
FY2021 EPS: The reported figure was 1.01 HK cents on 2,000 M pre-consolidation shares. It is restated here ×20 for the 20:1 consolidation (derived). FY2022 is already restated by the company.
DPS: The FY2021 final dividend was HK$0.0025 per pre-consolidation share (HK$5.0 M in total), equal to HK$0.05 per post-consolidation share (derived). The FY2022 final dividend was HK$0.05 per share (HK$5.0 M). FY2020's final was HK$0.005 per pre-consolidation share (HK$10.0 M).
Margins and growth
Revenue CAGR (derived):
-
FY2021→FY2025 (4 years): −4.9%.
-
FY2020→FY2025 (5 years, from HK$819.5 M): +0.9%.
-
Peak-to-current: FY2025 revenue is 36% below the FY2022 peak of HK$1,335.5 M.
Commentary — income statement. Wise Ally has never sustained operating margins above low single digits except in FY2024.
FY2021: Revenue rose 27.8% on post-COVID restocking and new customers. Gross margin slipped 60 bps on chip-shortage material inflation.
FY2022: Revenue peaked, but gross margin fell to 14.6% as component costs stayed elevated.
FY2023: Revenue fell 8.1% as customers cut over-stocked orders. Gross margin recovered to 17.2% on mix and lower material prices. Profit nonetheless collapsed to HK$1.2 M because of a HK$29.4 M fair-value loss on the TTL convertible bond, higher inventory provisions and higher finance costs at a 6.8% average borrowing rate.
FY2024: This was the inflection year. New-product ramps at key customers, richer mix and lower material costs lifted gross margin to 19.7%. A HK$19.2 M TTL fair-value gain swung other gains positive. Net profit reached a record HK$72.2 M.
FY2025: US tariffs from April 2025 caused deferrals and cuts at a few key customers. Revenue fell 32.2% and gross margin compressed 420 bps. Opex did not flex: S&D plus admin rose 2.9% to HK$176.9 M on sales commissions and the Batam ramp. The result was an operating loss of HK$20.9 M, even after a further HK$23.2 M TTL gain.
Underlying view: Excluding the TTL fair-value swings, the underlying (derived) operating result was approximately:
-
FY2022: HK$45.2 M
-
FY2023: HK$50.7 M
-
FY2024: HK$79.5 M
-
FY2025: −HK$44.1 M The FY2025 operating deterioration was therefore larger than headline figures suggest.
Balance sheet
Balance sheet note:
Classification: All bank borrowings are classified as current because of repayable-on-demand clauses. Only FY2021 had term instalments beyond one year (HK$10.5 M).
Currency: FY2025 borrowings were HK$30.7 M in HKD and HK$68.0 M in RMB, at a weighted average effective rate of 3.7% (FY2024: 5.7%; FY2023: 6.8%).
Latest position (30 June 2026): Commentary — balance sheet. The defining trend is aggressive deleveraging. Bank borrowings fell from HK$292.6 M at end-2023 to HK$61.2 M at June 2026, a 79% reduction (derived). This was funded by FY2024 cash generation and by working-capital release as revenue fell. Receivables fell from HK$368 M (2022) to HK$108 M (June 2026).
Equity rebuilt to HK$221.1 M in FY2024 but has since been eroded by losses. Equity of HK$135.7 M in June 2026 is the lowest since listing. Book value per share is HK$1.357.
Intangibles are negligible and there is no goodwill, so book value is close to tangible. Lease liabilities spiked in 2023 on the Chang'an renewal and are amortising toward the lease expiry on 31 March 2028.
Cash flow
Commentary — cash flow. Cash conversion has been the bright spot. OCF exceeded net profit in every year with data. FY2024 FCF of about HK$150 M was more than double net profit. Capex is light at roughly 1–1.7% of revenue, consistent with leased premises and a partner-owned Batam plant. The flip side is that a shrinking EMS business releases working capital, which flatters cash flow during a downturn. The 1H2026 receivables collection of HK$49.6 M is an example of this effect, and it is not repeatable indefinitely.
Ratios (derived unless stated)
Ratio notes:
ROE and ROA: FY2024–FY2025 ROE and ROA are company-reported (AR2025 Key Financial Ratios). FY2021–FY2023 are derived on the same method.
Invested capital: equity + bank borrowings + lease liabilities − cash − deposits. A notional 20% tax is used because effective tax rates are distorted by non-deductible fair-value items. For example, the FY2023 effective tax rate was about 77%.
Negative net debt/EBITDA: denotes net cash.
Commentary — ratios.
Returns: These track the single-year operating swing. The FY2024 ROE of 38.9% was exceptional, flattered by low equity and the TTL write-back.
Coverage: Interest coverage nearly broke in FY2023 (1.1x) at peak leverage and high rates, which coincided with covenant non-compliance.
Working capital: The CCC compressed from 120 days (FY2021, chip-shortage inventory build) to about 46–52 days, a structural working-capital improvement.
FY2025 inventory: The rise in DIO to 83 days flags inventory that did not fall in step with sales. Inventories were HK$157.7 M at June 2026 against 1H2026 cost of sales of HK$274.7 M, about 105 days annualised (derived).
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Segment Revenue
| Segment | What it contains | FY2023 revenue (HKD Mn) | FY2024 revenue (HKD Mn) | FY2025 revenue (HKD Mn) | FY2025 YoY | % of total |
|---|---|---|---|---|---|---|
Manufacturing and sale of electronic products | PCBAs, multifunctional modules, finished electronic products, and the associated design/engineering/supply-chain services, across appliances, commercial and industrial controls, HVAC, vapour products, IoT, medical/healthcare and consumer electronics | 1,227.2 | 1,260.8 | 855.0 | −32.2% | 100% |
Results by Segment and Segment Margins & Growth (%)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Segment revenue (HKD Mn) | 1,047.3 | 1,335.5 | 1,227.2 | 1,260.8 | 855.0 |
Segment gross profit (HKD Mn) | 194.3 | 195.0 | 210.6 | 247.9 | 132.2 |
Segment gross margin (%) | 18.5 | 14.6 | 17.2 | 19.7 | 15.5 |
Segment operating profit (HKD Mn) | 35.0 | 32.1 | 21.4 | 98.8 | -20.9 |
Segment pre-tax profit (HKD Mn) | 27.4 | 19.3 | 5.5 | 83.2 | -23.9 |
Revenue YoY growth (%) | 27.8 | 27.5 | -8.1 | 2.7 | -32.2 |
Results by Segment and Segment Margins & Growth (%) (1H2022–1H2026)
| Metric | 1H2022 | 1H2023 | 1H2024 | 1H2025 | 1H2026 |
|---|---|---|---|---|---|
Revenue (HKD Mn) | 547.8 | 546.6 | 563.5 | 469.9 | 311.7 |
Gross profit (HKD Mn) | 73.5 | 76.6 | 108.4 | 78.7 | 37.0 |
Gross margin (%) | 13.4 | 14.0 | 19.2 | 16.8 | 11.9 |
Operating profit (HKD Mn) | 9.3 | 4.5 | 28.4 | 18.2 | -53.0 |
EBITDA (HKD Mn) | 28.8 | 25.9 | 47.3 | 36.8 | — |
Net profit attributable (HKD Mn) | 3.5 | -1.6 | 15.7 | 14.3 | -54.6 |
Group Entities
| Entity | Jurisdiction | Role | Source |
|---|---|---|---|
Wise Ally International Holdings Limited | Cayman Islands | Listed holding company | AR2025 |
Wise Ally Holdings Limited ("HK Wise Ally") | Hong Kong | Indirect wholly owned subsidiary; sale of electronic products; counterparty to the TTL and Giken arrangements | JV announcement 20 Mar 2024 |
Dongguan Wise Ally Industrial Co., Ltd. (東莞威雅利實業有限公司) | PRC | Indirect wholly owned subsidiary; manufacturing and trading; tenant of the Chang'an plant | Tenancy announcement 6 Feb 2023 |
WiseGiken Elite Pte. Ltd. | Singapore | 90% HK Wise Ally / 10% Giken Sakata; sales and marketing of Batam-made EMS. Paid-up capital SGD2,000. | JV announcement 20 Mar 2024 |
Income Statement and Per-Share Data
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Revenue (HKD Mn) | 1,047.3 | 1,335.5 | 1,227.2 | 1,260.8 | 855.0 |
Cost of sales (HKD Mn) | 853.1 | 1,140.6 | 1,016.5 | 1,012.9 | 722.8 |
Gross profit (HKD Mn) | 194.3 | 195.0 | 210.6 | 247.9 | 132.2 |
Other gains/(losses), net (HKD Mn) | -14.7 | -9.8 | -29.2 | 23.1 | 22.5 |
Selling and distribution expenses (HKD Mn) | 52.4 | 52.2 | 53.1 | 54.3 | 57.6 |
Administrative expenses (HKD Mn) | 93.5 | 97.6 | 108.5 | 117.6 | 119.3 |
Operating profit (HKD Mn) | 35.0 | 32.1 | 21.4 | 98.8 | -20.9 |
EBITDA, company-reported (HKD Mn) | — | — | 62.9 | 135.9 | 17.0 |
Finance costs (HKD Mn) | 7.6 | 11.5 | 20.0 | 19.7 | 8.9 |
Pre-tax profit (HKD Mn) | 27.4 | 19.3 | 5.5 | 83.2 | -23.9 |
Income tax (HKD Mn) | 7.3 | 4.2 | 4.2 | 11.0 | 7.3 |
Net profit attributable (HKD Mn) | 20.1 | 15.1 | 1.2 | 72.2 | -31.2 |
EPS basic = diluted (HK cents, post-consolidation basis) | 20.1 | 15.1 | 1.2 | 72.2 | -31.2 |
DPS declared for the year (HK$, post-consolidation basis) | 0.05 | 0.05 | 0 | 0 | 0 |
Margin Analysis (%)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Gross margin (%) | 18.5 | 14.6 | 17.2 | 19.7 | 15.5 |
Operating margin (%) (derived) | 3.3 | 2.4 | 1.7 | 7.8 | -2.4 |
EBITDA margin (%) (derived) | — | — | 5.1 | 10.8 | 2.0 |
Net margin (%) | 1.9 | 1.1 | 0.1 | 5.7 | -3.6 |
Revenue growth YoY (%) | 27.8 | 27.5 | -8.1 | 2.7 | -32.2 |
Balance Sheet
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Total assets (HKD Mn) | 897.2 | 977.5 | 965.6 | 933.5 | 699.7 |
Cash and cash equivalents (HKD Mn) | 207.3 | 209.8 | 274.6 | 235.3 | 252.2 |
Bank / term deposits over 3 months (HKD Mn) | 0 | 32.4 | 0 | 48.6 | 12.4 |
Bank borrowings, all repayable on demand / within 1 yr (HKD Mn) | 249.9 | 275.3 | 292.6 | 188.3 | 98.7 |
Long-term bank debt (HKD Mn) | 0 | 0 | 0 | 0 | 0 |
Bills payable (HKD Mn) | 15.7 | 3.6 | 0 | 0 | 0 |
Lease liabilities, current (HKD Mn) | 17.2 | 13.0 | 19.8 | 24.0 | 20.2 |
Lease liabilities, non-current (HKD Mn) | 15.7 | 25.0 | 66.9 | 49.1 | 20.6 |
Net bank debt / (net cash), company definition (HKD Mn) | 42.6 | 33.1 | 18.0 | -95.6 | -165.9 |
Total equity (HKD Mn) | 152.7 | 156.0 | 150.3 | 221.1 | 189.5 |
Goodwill and intangibles (HKD Mn) | 0.9 | 0.7 | 0.6 | 0.3 | 0.4 |
Inventories (HKD Mn) | 288.7 | 227.8 | 223.8 | 196.3 | 164.9 |
Trade receivables, net (HKD Mn) | 275.2 | 368.3 | 297.8 | 270.9 | 157.8 |
Trade payables (HKD Mn) | 233.5 | 332.6 | 249.8 | 285.4 | 196.5 |
Working capital, current assets less current liabilities (HKD Mn) (derived) | 72.4 | 71.9 | 74.3 | 143.9 | 119.6 |
Financial Analysis
| Item | HKD Mn |
|---|---|
Cash | 195.1 |
Term deposits | 0 |
Borrowings | 61.2 |
Net cash | 133.9 |
Equity | 135.7 |
Total assets | 549.3 |
Inventories | 157.7 |
Receivables | 108.2 |
Payables | 160.9 |
Lease liabilities (17.7 current + 11.9 non-current) | 29.6 |
Cash Flow
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Operating cash flow (HKD Mn) | 34.3 | 88.0 | 91.8 | 164.0 | — |
Capex, PP&E plus intangibles additions (HKD Mn) | 16.9 | 14.6 | 13.8 | 10.4 | 14.6 |
Free cash flow, OCF less capex (HKD Mn) (derived) | 17.4 | 73.4 | 78.0 | 153.6 | — |
Dividends paid in year (HKD Mn) | 10.0 | 5.0 | 5.0 | 0 | 0 |
Share buybacks (HKD Mn) | 0 | 0 | 0 | 0 | 0 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
ROE, net / average equity (%) | 13.9 | 9.8 | 0.8 | 38.9 | -15.2 |
ROA, net / average total assets (%) | 2.4 | 1.6 | 0.1 | 7.6 | -3.8 |
ROIC, EBIT × (1 − 20% notional tax) / invested capital (%) | 12.3 | 11.3 | 6.7 | 39.8 | -32.5 |
Current ratio (x) | 1.10 | 1.09 | 1.10 | 1.22 | 1.25 |
Bank debt / equity (x) | 1.64 | 1.76 | 1.95 | 0.85 | 0.52 |
Net bank debt / EBITDA (x) | — | — | 0.29 | -0.70 | -9.76 |
Interest coverage, EBIT / finance costs (x) | 4.6 | 2.8 | 1.1 | 5.0 | -2.3 |
Asset turnover, revenue / average assets (x) | 1.28 | 1.42 | 1.26 | 1.33 | 1.05 |
Days inventory outstanding (days, year-end) | 123.5 | 72.9 | 80.4 | 70.7 | 83.3 |
Days sales outstanding (days, year-end) | 95.9 | 100.7 | 88.6 | 78.4 | 67.4 |
Days payables outstanding (days, year-end) | 99.9 | 106.4 | 89.7 | 102.8 | 99.2 |
Cash conversion cycle (days) | 119.5 | 67.2 | 79.3 | 46.3 | 51.5 |
Revenue by Region
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
United States (HKD Mn) | 460.3 | 363.8 | 391.3 |
Philippines (HKD Mn) | 228.1 | 377.2 | 138.0 |
Chinese Mainland (HKD Mn) | 53.2 | 197.1 | 102.0 |
Ireland (HKD Mn) | 87.7 | 104.0 | 49.6 |
Switzerland (HKD Mn) | 83.5 | 17.0 | 30.4 |
Germany (HKD Mn) | 30.4 | 17.7 | 25.2 |
Malaysia (HKD Mn) | 70.1 | 71.1 | 21.8 |
United Kingdom (HKD Mn) | 31.2 | 38.9 | 10.0 |
Singapore (HKD Mn) | 3.0 | 8.7 | 10.9 |
All other countries (HKD Mn) (derived residual) | 179.7 | 65.3 | 75.8 |
Total (HKD Mn) | 1,227.2 | 1,260.8 | 855.0 |
Geographic Revenue
| Metric | FY2024 vs FY2023 (%) | FY2025 vs FY2024 (%) |
|---|---|---|
United States | -21.0 | 7.6 |
Philippines | 65.4 | -63.4 |
Chinese Mainland | 270.5 | -48.3 |
Ireland | 18.6 | -52.3 |
Switzerland | -79.6 | 78.8 |
Germany | -41.7 | 42.7 |
Malaysia | 1.4 | -69.3 |
United Kingdom | 24.7 | -74.3 |
Singapore | 190.0 | 25.3 |
Revenue by Region and Revenue by Region (%)
| Metric | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
US revenue (HKD Mn) | 439.7 | 430.9 | 496.8 | 460.3 | 363.8 | 391.3 |
US share of revenue (%) | 53.7 | 41.1 | 37.2 | 37.5 | 28.9 | 45.8 |
Philippines revenue (HKD Mn) | 59.4 | 168.8 | 197.9 | 228.1 | 377.2 | 138.0 |
Revenue by Region (1H2025–1H2026)
| Metric | 1H2025 | 1H2026 |
|---|---|---|
United States (HKD Mn) | 174.4 | 200.2 |
Chinese Mainland (HKD Mn) | 71.1 | 24.5 |
Philippines (HKD Mn) | 111.3 | 20.0 |
Lithuania (HKD Mn) | 0 | 19.7 |
Switzerland (HKD Mn) | 15.0 | 13.3 |
Germany (HKD Mn) | 11.1 | 6.0 |
Singapore (HKD Mn) | 3.9 | 5.0 |
Mexico (HKD Mn) | 3.1 | 4.6 |
United Kingdom (HKD Mn) | 6.3 | 4.5 |
Netherlands (HKD Mn) | 1.8 | 3.1 |
Others (HKD Mn) | 72.0 | 10.8 |
Total (HKD Mn) | 469.9 | 311.7 |
Valuation Snapshot
| Metric | Value | Source / basis |
|---|---|---|
Last close (16 Oct 2026) | HK$1.02 | Tiger Brokers |
52-week range | HK$0.83 – 1.17 | Tiger Brokers |
Market cap | ≈HK$102 M | Tiger Brokers |
Typical daily volume | Very thin; e.g., 10,000 shares on 16 Oct 2026 (turnover 0.01%) | Tiger Brokers |
IPO price (adjusted for 20:1 consolidation) | HK$5.00 (HK$0.25 × 20) | Derived |
Metric | 1-year | 3-year |
Share price change, price only (%) (derived) | 0.0 | 64.5 |
Capital Markets
| Metric | Wise Ally | Basis |
|---|---|---|
P/E (trailing) | n.m. (loss) | TTM net loss ≈HK$100.1 M (FY2025 −31.2, less 1H2025 +14.3, plus 1H2026 −54.6); TTM EPS ≈ −HK$1.00 |
P/B | 0.75x | BVPS HK$1.357 (30 Jun 2026) |
EV (ex-leases) | ≈ −HK$32 M | HK$102 M + debt 61.2 − cash 195.1 |
EV (incl. leases) | ≈ −HK$2 M | Adds lease liabilities of HK$29.6 M |
EV/Sales (TTM revenue ≈HK$696.8 M) | n.m. (negative EV) | — |
Price / sales (TTM) | 0.15x | — |
Net cash / market cap | ≈131% | HK$133.9 M / HK$102 M |
Per-Share Data and Dividends & Capital Returns
| Metric | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
DPS declared (HK$, post-consolidation basis) | 0.10 | 0.05 | 0.05 | 0 | 0 | 0 |
Total dividend (HKD Mn) | 10.0 | 5.0 | 5.0 | 0 | 0 | 0 |
Capital Markets — Buyback authorisation
| Item | Detail |
|---|---|
Buyback authorisation | AGM general mandate to repurchase up to 10% of shares (approved 1 Jun 2026). No repurchases have been executed since listing, and no treasury shares are held. |
Issuance mandate | Up to 20% general mandate (2026 AGM) |
Credit ratings (Moody's / S&P / Fitch) | None; unrated |
Debt maturity profile (30 Jun 2026) | Bank borrowings HK$61.2 M, all repayable within 1 year / on demand. Lease liabilities HK$17.7 M current and HK$11.9 M non-current, amortising to the Chang'an lease end (31 Mar 2028). No bonds outstanding. |
Analyst Conclusions
Management guidance
There is no quantitative guidance. In the 1H2026 interim, management expects the rest of 2026 to remain challenging. Its stated priorities are:
-
expanding the client portfolio;
-
diversifying production (Batam);
-
consolidating manufacturing facilities;
-
conservative procurement and inventory management;
-
strict receivables enforcement;
-
continued debt reduction.
Cited headwinds are tariffs, component inflation, RMB appreciation, geopolitical logistics disruption and weak consumer confidence.
Consensus expectations
None available, as there is no sell-side coverage.
Bull case (grounded in the data)
-
Asset backing with a free option. Net cash of HK$133.9 M exceeds the HK$102 M market cap, and P/B is 0.75x. The market is pricing the operating business at a negative value. Any stabilisation, even at breakeven, could re-rate the equity toward book.
-
US/Batam momentum. US revenue rose to HK$200.2 M in 1H2026 (+14.8% YoY) while non-US revenue collapsed. As the Philippines/Mainland legacy programmes finish rolling off, the revenue base will be rebuilt on new US customers served from tariff-advantaged Batam.
-
Restructuring leverage. FY2024 showed that HK$1.26 bn of revenue at about 20% gross margin yields HK$99 M operating profit. Cutting the HK$87 M half-year opex run-rate via facility consolidation, while the deleveraged balance sheet eliminates interest drag, could return the group to profit at a lower revenue level than before.
Bear case (grounded in the data)
-
Revenue cliff and concentration. Revenue fell from HK$1,260.8 M (FY2024) to an annualised run-rate of about HK$623 M (1H2026 × 2, derived). This happened despite the US and Batam story. Two customers account for about 29% of 1H2026 sales, and further programme losses would be existential for scale.
-
Margin structurally impaired. Gross margin fell to 11.9% in 1H2026 because of component inflation tied to AI/EV demand and RMB appreciation, which are structural rather than cyclical. Opex of about HK$87 M per half far exceeds gross profit of HK$37 M.
-
Cash buffer is wasting. Equity fell HK$53.8 M in six months. Working-capital release, which has kept cash flow positive, diminishes as the business shrinks. Restructuring may also bring lease-exit costs (six months' rent compensation on early termination of the Chang'an lease) and severance.
Key catalysts and monitorables (next 12 months)
| Catalyst / monitorable | Expected timing |
|---|---|
| Details and cost of the manufacturing facility consolidation (site, severance, lease exit) | 2H2026 – FY2026 results |
| FY2026 profit warning / results (March 2027): size of 2H2026 loss, impairments, inventory provisions | Mar 2027 |
| US–China tariff developments and US customer order trends | Ongoing |
| Batam capacity expansion or new customer announcements | Ongoing |
| Component price trajectory (memory, semiconductors) | Ongoing |
| Gross margin recovery above 15% | 2H2026 / 1H2027 |
| Cash and net-cash trajectory (HK$133.9 M at June 2026) | Dec 2026 balance sheet |
| Chang'an lease strategy ahead of the 31 Mar 2028 expiry | 2,027 |
| Any controlling-shareholder action (privatisation, capital return) given sub-book valuation | Unpredictable |
| Founder succession / governance (Chair-CEO separation) | Ongoing |
Analyst verdict
Wise Ally is a classic small-cap, founder-controlled EMS operator. Its investment case has migrated from operating story to balance-sheet story within eighteen months.
FY2024 showed what the platform can earn when a few key programmes ramp with favourable mix: HK$247.9 M gross profit, HK$98.8 M operating profit and a 38.9% ROE. Since April 2025 that same concentration has worked in reverse. Tariff-driven order deferrals, the apparent roll-off of the Philippines- and Mainland-delivered programmes, and AI/EV-driven component inflation cut revenue by a third in successive periods. Gross margin fell to 11.9%. Fixed costs did not flex, producing a HK$54.6 M first-half loss.
Management's response has been disciplined on the balance sheet. Borrowings have fallen 79% since 2023, interest is fully covered by deposit income, and net cash is HK$133.9 M. It has also been directionally sensible on operations, through the Batam China Plus One pivot and now facility consolidation. Its credibility, however, rests on execution it has not yet quantified: no savings targets, no capacity numbers and no customer disclosures.
At HK$1.02 the shares trade at 0.75x book and below net cash, with essentially zero liquidity and no sell-side coverage. The equity therefore behaves as a deep-value, event-driven instrument. Downside is cushioned by cash but threatened by the rate at which losses consume it. At the 1H2026 loss rate, the cash cushion could shrink materially within a year or two absent restructuring. Upside depends on restructuring traction and US/Batam growth, or on the controlling family acting to realise value.
Verdict: a high-risk special situation suitable only for patient, liquidity-tolerant capital. The key monitorables are the restructuring charge and savings, 2H2026 gross margin, and whether US revenue growth can outpace the legacy roll-off. Absent clear evidence by the FY2026 results in March 2027, the balance-sheet discount is likely to persist rather than close.
Prepared from public sources as of 17 October 2026. Figures are in HK$ for fiscal years ending 31 December unless stated. "Derived" denotes analyst calculation from filed figures. "Not publicly disclosed" or "n/a" denotes data not available in the reviewed public record. Aggregator-sourced data (TipRanks, Tiger Brokers, Morningstar, Yahoo, etnet) is identified where used and should be cross-checked against the primary filings on hkexnews.hk.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Board of Directors
| Name | Title | Appointed / tenure | Age (AR2025) | Prior roles | Education |
|---|---|---|---|---|---|
Chu Wai Hang Raymond (朱慧恒) | Chairman, Executive Director, CEO (CEO since 30 Sep 2021); founder; controlling shareholder; Remuneration and Nomination Committee member | Group founder (2010). Director since listing; CEO since 2021. | 73 | Defond Holdings (H.K.) from June 1990 as chairman responsible for technical/IT/R&D, then EMS division management. Engineer at an electromechanical motion systems company, 1977–early 1990s. | BSc Mechanical Engineering, UC Berkeley (1977) |
Chu Man Yin Arthur Newton (朱文彥) | Executive Director; MD, original brand development (New Branded Division) | Joined Jan 2021; ED since 2 Jul 2021 (service term renewed from 1 Jul 2024 for 3 years) | 43 | R&D senior manager, Cornerstone Developments (LED lighting), 2015–2021. Defond Electrical Industries 2008–2015 (mechanical engineer → senior programme manager → R&D senior manager). | BSc Mechanical Engineering, University of Southern California (2006) |
Lau Shui Fung (劉士峯) | Executive Director; CFO | CFO since 31 Oct 2021; ED since 1 Dec 2021 (renewed from 1 Dec 2024) | 59 | CFO / VP Finance and Company Secretary, Defond Holdings, 2016–2021. VP Finance, Computime Group, 2013–2016. Nam Tai Electronics 2001–2013 (VP Finance, Group FC). INED of Nam Tai Property (2018–19) and Kaisa Health (2019–20). | BCom Accounting (Univ. of Southern Queensland); MPA (HK PolyU); FCPA (HK), CPA Australia, FAIA |
Wei Andrew Yick Siu (韋益兆) | Executive Director (elected at AGM 1 Jun 2026); Chief Marketing Officer of Wise Ally Holdings since Jan 2023 | Joined Aug 2021 (VP client base management) | 56 | Director of programme management – IoT, PC Partner EMS division, 2017–2021. Electronics Tomorrow Ltd 2000–2017 (rising to COO). | BA, University of Toronto (1992) |
Lo Wing Yan Emmy (盧穎欣)* | Independent Non-executive Director; Audit Committee chair; Remuneration and Nomination Committee member | Elected 1 Jun 2026 | not disclosed in reviewed docs | Financial controller, Jimu Group. Previously CFO, executive director and company secretary of Omnibridge. | Hong Kong CPA |
Lee Wa Lun Warren (李華倫) | INED; Nomination Committee chair; Audit and Remuneration Committee member | Since 10 Dec 2019; re-elected 2026 | 62 | MD and founding director of Yu Ming Investment Management (1996–). ED of Da Yu Financial (1073). Former chairman of SHK Hong Kong Industries. CEO of Nam Tai Electronics (Dec 2006 – May 2007). INED of TIH Ltd (SGX) since May 2024. SFC responsible officer. | BSc (University of East Anglia, 1986); MSc with distinction (City University Business School, 1988) |
Szeto Yuk Ting (司徒毓廷) | INED; Remuneration Committee chair; Audit and Nomination Committee member | Since 10 Dec 2019 | 58 | Practising HK solicitor; sole proprietor of Szeto & Co., Y.T. INED of Evergreen Products (1962) and Chiho Environmental (976). | LLB and PCLL (University of Hong Kong) |
Executive Leadership Team
| Name | Role | Since | Background |
|---|---|---|---|
Chan Wai Ho (陳偉豪) | General Manager (production operations) | 6 April 2020 | 30+ years in EMS. Meter Technology (Towngas subsidiary); IDT Technology (head of manufacturing); Rohm and Haas Electronic Materials. BEng (Liverpool John Moores); MBA (University of South Wales, Nov 2025); Certified ESG Planner (Jan 2026). |
Choi Yuet Mei Mercury (蔡月媚) | VP, Supply Base Management | October 2021 | About 30 years in procurement. Karrie Group (AGM procurement); Shenzhen Sea Star Technology (Vice GM). MSc Logistics and Operations Management (Macquarie). |
Chan Sau Ling (陳秀玲) | Company Secretary; authorised representative | Since Oct 2021 (change of company secretary announced 29 Oct 2021) | Not detailed in reviewed docs |
Governance Overview
| Item | Detail | Source |
|---|---|---|
CEO pay terms (set on appointment, 2021) | HK$2,600,000 per annum plus a year-end performance bonus equal to 3% of audited net profit after tax | Announcement 1 Sep 2021 |
Senior management pay bands FY2025 | 1 person in HK$1.0–1.5 M; 1 person in HK$1.5–2.0 M; 2 persons in HK$2.0–2.5 M | AR2025 CG Report |
Share incentives | Share Option Scheme adopted 10 Dec 2019 (valid to 9 Jan 2030). No options ever granted. Mandate of 10,000,000 shares (10%). | AR2025 |
Board meetings FY2025 | 5 meetings, 100% attendance by all directors. Audit Committee met 6 times (100%). Remuneration Committee met once. | AR2025 CG Report |
Board & Management Changes
| Date | Change | Context |
|---|---|---|
2 Jul 2021 | Arthur Chu appointed ED | Led the New Branded Division |
30 Sep 2021 | CEO Tsang Ming Chit Stanley resigned; Raymond Chu became CEO | Resignation for personal endeavours; no disagreement with the board |
31 Oct 2021 | COO and ED Chan Chi Ming resigned. Lau Shui Fung became CFO (ED from 1 Dec 2021). | Personal endeavours; COO role not refilled per disclosures |
1 Jun 2023 | INED Ling Imma Kit Sum retired; Law Elizabeth elected | Routine rotation |
1 Jun 2026 | INED Law Elizabeth retired. Lo Wing Yan Emmy elected INED and Audit chair. Wei Andrew elected ED. | Board refresh. All AGM resolutions passed with 100% of votes cast (about 16.78 M shares voted, per Bulletin Express summary). |
Major Shareholders
| Holder | Shares | % of issued | Nature |
|---|---|---|---|
Smartview Investments Limited | 51,000,000 | 51.0% | Beneficial. Owned 50% by Raymond Chu and 50% by Wilson Chu. |
Smart Union Global Group Limited | 12,000,000 | 12.0% | Beneficial; 100% owned by Raymond Chu |
Grandview Group Holdings Limited | 12,000,000 | 12.0% | Beneficial; 100% owned by Wilson Chu |
Mr. Chu Wai Hang Raymond (deemed) | 63,000,000 | 63.0% | Via Smart Union and Smartview |
Mr. Chu Wai Cheong Wilson (deemed) | 63,000,000 | 63.0% | Via Grandview and Smartview |
Ms. Tam Wai Yee Czarina (spouse of Raymond) | 63,000,000 | 63.0% | Spousal interest |
Ms. Ng Ching Annetta (spouse of Wilson) | 63,000,000 | 63.0% | Spousal interest |
Competitive Landscape
Key Competitors
| Competitor | Listing | Overlap with Wise Ally | Latest revenue (as verified) | Positioning vs Wise Ally |
|---|---|---|---|---|
Computime Group | HKEX: 320 | Control solutions (HVAC/thermostats, appliance controls), EMS plus branded; Southeast Asia/Mexico footprint | FY2026 (Mar YE): HK$4,104.9 M (+2.7%); profit HK$20.3 M | About 5x larger; diversified footprint (China, Malaysia, Vietnam, Mexico, Romania) and own brands |
Kimball Electronics | Nasdaq: KE | Medical, industrial, automotive EMS | FY2026 (Jun YE): US$1,431.4 M (−4%); operating margin 4.6% | Much larger, multinational plants, stronger medical franchise |
Deswell Industries | Nasdaq: DSWL | Electronics EMS (pro-audio, instruments) plus plastics, Dongguan-based | FY2026 (Mar YE): US$61.3 M (−9.3%); net income US$10.6 M | Smaller but highly profitable, net-cash Dongguan peer |
Jabil | NYSE: JBL | Appliance, healthcare, consumer EMS at scale | — | Tier-1; competes for the largest accounts |
Flex | Nasdaq: FLEX | Appliances, medical, industrial EMS | — | Tier-1 |
Sanmina | Nasdaq: SANM | Industrial, medical EMS | — | Tier-1 / high-reliability |
Benchmark Electronics | NYSE: BHE | Medical, industrial EMS | — | Mid/Tier-2, high-mix specialist |
Plexus | Nasdaq: PLXS | Healthcare/life sciences, industrial EMS | — | High-mix leader with Malaysia footprint |
PC Partner Group (EMS division) | SGX: PCT (delisted from HKEX 14 Jan 2026) | IoT / ODM EMS; source of Wise Ally's CMO | — | HK-heritage EMS peer |
IDT International | HKEX: 167 | Consumer electronics/instruments design and manufacture | — | HK ODM peer |
VS Industry | Bursa Malaysia | Box-build EMS for consumer/appliance brands | — | Malaysia scale player benefiting from China Plus One |
Giken Sakata / GSS Energy | SGX: 41F | Batam EMS (also Wise Ally's partner) | — | Partner and potential competitor |
Peer Comparison FY2025
| Metric | Wise Ally (FY Dec-25) | Computime (FY Mar-26) | Kimball (FY Jun-26) | Deswell (FY Mar-26) |
|---|---|---|---|---|
Revenue (local, M) | HK$855.0 | HK$4,104.9 | US$1,431.4 | US$61.3 |
Revenue growth (%) | -32.2 | 2.7 | -3.7 | -9.3 |
Operating margin (%) | -2.4 | — | 4.6 | — |
Net margin (%) | -3.6 | 0.5 (derived) | — | 17.3 (derived) |
Recent Developments
Every identifiable event is listed, with context entries from February–March 2025 where they directly shaped the period.
Headcount reduction is disclosed only via period-end employee numbers.
